Eslami, M.; Monemi, M.; Nazari, M.A.; Azami, M.H.; Shariat Rad, P.; Oksenych, V.; Naderian, R.
The Anti-Inflammatory Potential of Tricyclic Antidepressants (TCAs): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology. Pharmaceuticals 2025, 18, 197.
https://doi.org/10.3390/ph18020197
AMA Style
Eslami M, Monemi M, Nazari MA, Azami MH, Shariat Rad P, Oksenych V, Naderian R.
The Anti-Inflammatory Potential of Tricyclic Antidepressants (TCAs): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology. Pharmaceuticals. 2025; 18(2):197.
https://doi.org/10.3390/ph18020197
Chicago/Turabian Style
Eslami, Majid, Marzieh Monemi, Mohammad Ali Nazari, Mohammad Hossein Azami, Parand Shariat Rad, Valentyn Oksenych, and Ramtin Naderian.
2025. "The Anti-Inflammatory Potential of Tricyclic Antidepressants (TCAs): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology" Pharmaceuticals 18, no. 2: 197.
https://doi.org/10.3390/ph18020197
APA Style
Eslami, M., Monemi, M., Nazari, M. A., Azami, M. H., Shariat Rad, P., Oksenych, V., & Naderian, R.
(2025). The Anti-Inflammatory Potential of Tricyclic Antidepressants (TCAs): A Novel Therapeutic Approach to Atherosclerosis Pathophysiology. Pharmaceuticals, 18(2), 197.
https://doi.org/10.3390/ph18020197